ARTICLE | Company News
The university granted Lin Bioscience exclusive, worldwide rights to preclinical candidate LBS-008 and related IP. Lin expects to move the retinol binding protein 4 plasma (RBP4) inhibitor into Phase I testing this year to treat dry age-related macular degeneration (AMD) and Stargardt's disease. ...
BCIQ Company Profiles
BCIQ Target Profiles